Layoffs
Agios axes 100-plus R&D roles while awaiting FDA decision
Key Facts
Signal Type
Layoffs
Industry
Biotech
Companies
Agios Pharmaceuticals, Truist Securities, Leerink Partners, Novo Nordisk
Date
November 6, 2026
Agios Pharmaceuticals announced a restructuring that eliminates over 100 R&D positions, representing more than 35% of its R&D team. The company expects to incur approximately $11 million in restructuring charges in 2026, with cost savings realized in 2027. CEO Brian Goff stated the move 'right sizes' the operating model to maximize the mitapivat franchise.
The layoffs primarily impact R&D staff at the Massachusetts-based biopharma, which employed 539 full-time workers as of December 2025. Agios is focusing on commercialization and late-stage development of two rare hematology candidates, while deprioritizing early-stage assets like AG-181.
Analysts view the restructuring favorably. Truist Securities noted 'cost discipline provides another lever toward profitability.' Leerink Partners said the R&D headcount reduction reflects 'sharper allocation of capital toward commercialization.' Agios now estimates profitability (excluding irregular costs) by 2028. The company had $907 million in cash as of September 30. The FDA delay on mitapivat for sickle cell disease pushed the decision to February 2027, causing a stock decline.
The FDA's decision on mitapivat for sickle cell disease, now expected by February 1, 2027, will be a key catalyst. Agios is also open to unlocking value from non-core assets, which could lead to partnerships or divestitures. The company's ability to execute its commercial strategy and achieve profitability in 2028 will be closely monitored.
Source:
BioSpaceGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
